The broad spectrum HDAC inhibitor SAHA (also known as Zolinza® or Vorinostat) was the first HDAC inhibitor to have successfully completed clinical trials and is used for the treatment of cutaneous T-cell lymphoma (7). This evidence concerns the gene HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma.